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Abstract
BACKGROUND—Nitrates are commonly prescribed to enhance activity tolerance in patients 
with heart failure and a preserved ejection fraction. We compared the effect of isosorbide 
mononitrate or placebo on daily activity in such patients.
METHODS—In this multicenter, double-blind, crossover study, 110 patients with heart failure 
and a preserved ejection fraction were randomly assigned to a 6-week dose-escalation regimen of 
isosorbide mononitrate (from 30 mg to 60 mg to 120 mg once daily) or placebo, with subsequent 
crossover to the other group for 6 weeks. The primary end point was the daily activity level, 
quantified as the average daily accelerometer units during the 120-mg phase, as assessed by 
patient-worn accelerometers. Secondary end points included hours of activity per day during the 
120-mg phase, daily accelerometer units during all three dose regimens, quality-of-life scores, 6-
minute walk distance, and levels of N-terminal pro–brain natriuretic peptide (NT-proBNP).
RESULTS—In the group receiving the 120-mg dose of isosorbide mononitrate, as compared with 
the placebo group, there was a nonsignificant trend toward lower daily activity (−381 
accelerometer units; 95% confidence interval [CI], −780 to 17; P = 0.06) and a significant 
decrease in hours of activity per day (−0.30 hours; 95% CI, −0.55 to −0.05; P = 0.02). During all 
dose regimens, activity in the isosorbide mononitrate group was lower than that in the placebo 
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group (−439 accelerometer units; 95% CI, −792 to −86; P = 0.02). Activity levels decreased 
progressively and significantly with increased doses of isosorbide mononitrate (but not placebo). 
There were no significant between-group differences in the 6-minute walk distance, quality-of-life 
scores, or NT-proBNP levels.
CONCLUSIONS—Patients with heart failure and a preserved ejection fraction who received 
isosorbide mononitrate were less active and did not have better quality of life or submaximal 
exercise capacity than did patients who received placebo.
Approximately half of patients with heart failure have a preserved ejection fraction.1 
Exercise intolerance is a cardinal feature of this syndrome and perpetuates sedentary 
behavior, deconditioning, and frailty.2–4 In early studies in patients with heart failure with a 
reduced ejection fraction, long-acting nitrates improved activity tolerance, as assessed by 
submaximal5,6 or maximal7 exercise tests. Although nitrates are commonly prescribed for 
symptom relief in heart failure,8–12 the effects of nitrates in patients with heart failure and a 
preserved ejection fraction have not been extensively studied. The hemodynamic effects of 
nitrates might attenuate pulmonary congestion with exertion and improve exercise capacity 
in heart failure with a preserved ejection fraction.13 However, the unique pathophysiology, 
associated coexisting illnesses, and polypharmacy that are characteristic of heart failure with 
a preserved ejection fraction may limit hemodynamic improvements and predispose patients 
to excessive hypotension or other side effects with nitrates.14–17 Thus, the overall effect of 
nitrates on activity tolerance in such patients is uncertain.
In assessing activity tolerance, intermittent supervised exercise tests may not reflect the full 
effect of a therapy on a patient’s daily functional status. Patient-worn accelerometers 
provide continuous assessment of physical activity during daily life and may more 
accurately reflect the effect of a therapy on functional status.18,19 Accordingly, we 
performed the Nitrate’s Effect on Activity Tolerance in Heart Failure with Preserved 
Ejection Fraction (NEAT-HFpEF) trial to test the hypothesis that extended-release isosor-
bide mononitrate would enhance the daily activity level in patients with heart failure with a 
preserved ejection fraction, as assessed by patient-worn accelerometers.13
METHODS
STUDY OVERSIGHT
The NEAT-HFpEF trial was sponsored by the National Heart, Lung, and Blood Institute. 
The protocol was approved by the protocol review committee of the institute’s Heart Failure 
Clinical Research Network and monitored by the network’s data and safety monitoring 
board. The ethics committee at each participating site approved the trial design. Data 
collection, management, and analysis were performed at the network’s data coordinating 
center at Duke Clinical Research Institute. All the authors reviewed and approved the 
manuscript and assume full responsibility for the accuracy and completeness of the data and 
for the fidelity of this report to the study protocol, which is available with the full text of this 
article at NEJM.org.
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STUDY PATIENTS
Ambulatory patients with a diagnosis of heart failure were eligible if they were 50 years of 
age or older and had heart failure while they were receiving stable medical therapy. Patients 
were required to have an ejection fraction of 50% or more and objective evidence of heart 
failure, as shown by one or more of the following criteria within 12 months before 
enrollment: previous hospitalization for heart failure with radiographic evidence of 
pulmonary congestion, elevated left ventricular end diastolic pressure at rest (≥15 mm Hg) 
or elevated pulmonary capillary wedge pressure at rest (≥20 mm Hg) or with exercise (≥25 
mm Hg), an elevated level of N-terminal pro–brain natriuretic peptide (NT-proBNP) (>400 
pg per milliliter) or brain natriuretic peptide (BNP) (>200 pg per milliliter), or Doppler 
echocardiographic evidence of diastolic dysfunction. In addition, patients were required to 
report on a screening questionnaire that the primary reason for their inability to be active 
was a history of dyspnea, fatigue, or chest pain (rather than orthopedic, neurologic, or 
lifestyle factors).
Exclusion criteria included a systolic blood pressure of less than 110 mm Hg or greater than 
180 mm Hg or a previous adverse reaction to or current use of long-term nitrate or 
phosphodiesterase type 5 inhibitor therapy. The full entry criteria are provided in Tables S1 
and S2 in the Supplementary Appendix, available at NEJM.org. All the patients provided 
written informed consent.
STUDY DESIGN
The design of the trial, which was a multicenter, randomized, double-blind, placebo-
controlled, crossover study, has been described previously.13 After enrollment, patients 
underwent baseline studies, including echocardiography (with results read centrally at Duke 
Echocardiography Laboratory), and assessments of secondary end points, including quality-
of-life scores, distance on the 6-minute walk test, and core laboratory assessment of NT-
proBNP.13
Patients were supplied with a belt outfitted with two kinetic activity monitors (Kersh Health) 
containing high-sensitivity, triaxis accelerometers (KXUD9-2050, Kionix) (Fig. S1 in the 
Supplementary Appendix). Patients were instructed to wear the accelerometers 24 hours per 
day except while bathing or swimming. Each accelerometer was matched to a patient by 
means of a serial number and activated at the time it was dispensed, providing time- and 
date-stamped data synchronized to the study protocol.
The accelerometers measure movement, as described in the Supplementary Appendix. The 
accelerometer measurements are expressed as arbitrary accelerometer units. These are stored 
as 15-minute cumulative accelerometer units (96 data points per day). The 15-minute 
cumulative accelerometer units were totaled over a 24-hour period to provide daily 
accelerometer units.
Permuted-block randomization that was stratified according to study site was used to assign 
patients in a 1:1 ratio to one of two treatment groups (6 weeks of placebo first with 
crossover to 6 weeks of isosorbide mononitrate or 6 weeks of isosorbide mononitrate first 
with crossover to 6 weeks of placebo). According to the crossover design, the same patients 
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were compared during the two treatment periods. The study drugs were prepared as 30-mg 
tablets of isosorbide mononitrate and matching placebo (University of Iowa 
Pharmaceuticals).
During each 6-week period, patients were instructed to take no study drug for the first 2 
weeks (baseline phase during the first period and wash-out phase during the second period), 
followed by one tablet (30 mg daily) for 1 week, two tablets (60 mg once daily) for 1 week, 
and four tablets (120 mg once daily) until the next study visit, for a treatment duration of at 
least 2 weeks and up to 4 weeks. Patients were called weekly to assess any side effects and 
reinforce compliance with study procedures. Patients who had unacceptable side effects 
were allowed to return to the previous dose. After the first period, patients returned to the 
study center to repeat end-point assessments, receive the crossover study drug, and exchange 
accelerometers. After the second period, patients returned to repeat end-point assessments 
and to return the accelerometers and any unused tablets of isosorbide mononitrate or placebo 
provided during the second period.
OUTCOME MEASURES
The prespecified primary end point was a comparison of average daily accelerometer units 
during the period in which patients were receiving the 120-mg dose of isosorbide 
mononitrate as compared with placebo. In addition, two other accelerometer-derived activity 
end points were prespecified. The average hours of activity per day during the 120-mg dose 
were calculated from the daily number of 15-minute cumulative accelerometer units greater 
than 50 (activity threshold). (Details are provided in the Methods section in the 
Supplementary Appendix.) To assess activity during the entire duration of study-drug 
administration, the area under the curve for time and daily accelerometer units during the 
receipt of all three doses (30 mg, 60 mg, and 120 mg) of study drug was divided by the total 
days of the regimen. Finally, a dose–response analysis compared the change in average daily 
accelerometer units from baseline at each dose. The accelerometer core laboratory at the 
Mayo Clinic processed the data.
Other secondary end points included the 6-minute walk distance and the post-walk Borg 
dyspnea score, scores on the Kansas City Cardiomyopathy Questionnaire and the Minnesota 
Living with Heart Failure Questionnaire, and NT-proBNP levels. At the end of the study, 
patients completed a questionnaire indicating in which period they felt better (first period, 
second period, or no preference).
STATISTICAL ANALYSIS
Since no previous heart-failure studies have used the primary outcome measure that we used 
in our study, we based our power calculations on previous data for the secondary end points 
in heart-failure trials. In a crossover design, we estimated that the enrollment of 94 patients 
would have a power of 80% to detect a minimal clinically significant difference of 5 points 
on the clinical summary score of the Kansas City Cardiomyopathy Questionnaire and that 
the enrollment of 60 patients would provide a power of more than 90% to detect a minimal 
clinically significant difference of 43 m in the 6-minute walk dis-tance.13 Estimates derived 
from reproducibility data with a different accelerometer in 49 elderly, sedentary volunteers 
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indicated that the enrollment of 100 patients would provide a power of 90% to detect a 
relative treatment effect of approximately 2.5% of the baseline measurement.13,20 The target 
enrollment was approximately 100 patients.
For all crossover end points, the analysis was performed on an intention-to-treat basis and 
used a linear mixed model with fixed-effect terms for the sequence, study period, and 
treatment.21 A random-effect term was included to account for the correlated measurements 
for each patient.22 For the primary end point, sensitivity analyses included the mixed model 
with 100 multiple imputations for missing data and an analysis that used a paired t-test in a 
crossover design structure (treatment and period effect terms) in patients with data for the 
two study periods. A general linear model was used to determine whether the average daily 
accelerometer units during each dose period differed from baseline in the two study groups. 
This analysis was not adjusted for any between-group differences at baseline. A two-sided P 
value of 0.05 was considered to indicate statistical significance. For the primary end point, 
interaction between treatment effect and a number of prespecified baseline characteristics 
was assessed.
RESULTS
STUDY PATIENTS
From April 7, 2014, to October 30, 2014, a total of 110 patients with chronic heart failure 
were enrolled at 20 sites in the United States, with 51 patients assigned to receive isosorbide 
mono-nitrate first and placebo second and 59 patients assigned to receive placebo first and 
isosorbide mononitrate second (Fig. S2 in the Supplementary Appendix). The median 
duration of heart failure was 1.8 years. The mean age of the patients was 69 years, and 57% 
were women. The majority of the patients were white and obese, with controlled blood 
pressure and multiple coexisting illnesses; most of the patients were taking multiple 
cardiovascular medications (Table 1). Nearly all the patients had New York Heart 
Association functional class II or III symptoms; 2 patients in the first placebo group had 
class I or IV symptoms. The mean ejection fraction was 63%, and 47% of the patients had 
evidence of concentric remodeling or hypertrophy, with a relative wall thickness (defined as 
the sum of the intraventricularseptum and posterior-wall diastolic thicknesses divided by the 
diastolic cavity dimension) of more than 0.41.
PRIMARY AND SECONDARY ACTIVITY END POINTS
During the 120-mg phase, 101 patients during the first period and 91 during the second 
period had usable accelerometer data, with a median of 16 complete days of accelerometer 
data (inter-quartile range, 12 to 20) during the first period and 14 complete days 
(interquartile range, 10 to 18) during the second period (P<0.001) (Fig. S2 in the 
Supplementary Appendix). The average daily accelerometer units, as assessed by the two 
accelerometers worn by each patient, were highly correlated (r=0.99) (Fig. S3 in the 
Supplementary Appendix).
For the primary end point of average daily accelerometer units during the 120-mg phase, 
there was a nonsignificant trend (P = 0.06) toward lower activity during receipt of isosorbide 
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mononitrate than during receipt of placebo, with a treatment effect of −381 accelerometer 
units per day (95% confidence interval [CI], −780 to 17) (Table 2 and Fig. 1A). Similar 
treatment effects were revealed on the basis of sensitivity analyses using multiple imputation 
(−365 accelerometer units per day; 95% CI, −754 to 23; P = 0.07), paired t-test crossover 
analysis (−402 accelerometer units per day; 95% CI, −794 to −9; P = 0.04), and analysis 
restricted to patients who were receiving a study drug during the end-point assessment (−306 
accelerometer units per day; 95% CI, −745 to 141; P = 0.18).
Patients were active for fewer hours of the day (−0.30 hours; 95% CI, −0.55 to −0.05; P = 
0.02) during the 120-mg phase of receipt of isosorbide mononitrate as compared with 
placebo (Table 2 and Fig. 1B). During all study-drug regimens combined (30 mg to 120 
mg), patients were less active (−439 accelerometer units per day; 95% CI, −792 to −86; P = 
0.02) during receipt of isosorbide mononitrate as compared with placebo (Table 2 and Fig. 
1C). As compared with baseline, average daily accelerometer units decreased with 
increasing doses of isosorbide mononitrate but not placebo (Fig. 2). For the primary end 
point, there were no significant interactions between treatment effect and baseline 
characteristics (Fig. 3).
OTHER SECONDARY END POINTS
As compared with placebo, there was no significant effect of isosorbide mononitrate on the 
6-minute walk distance or post-walk Borg dyspnea score, the clinical summary score on the 
Kansas City Cardiomyopathy Questionnaire, the total score on the Minnesota Living with 
Heart Failure Questionnaire, or the NT-proBNP level (Table 2). Although the treatment 
differences were not significant, the direction of the numerical effects on quality-of-life 
scores and NT-proBNP levels were unfavorable for isosorbide mononitrate. As compared 
with placebo, isosorbide mono-nitrate decreased blood pressure (Table 2). Similar 
proportions of patients indicated that they felt better during receipt of isosorbide mononitrate 
(36%) or receipt of placebo (30%), and 33% had no preference.
Numerically, more patients discontinued isosorbide mononitrate than placebo (Fig. S2 in the 
Supplementary Appendix). Numerically, more patients had adverse events of interest while 
receiving isosorbide mononitrate than while receiving placebo (Table 2). There were five 
serious adverse events in three patients during the study (in two patients during the 
isosorbide mononitrate phase and one patient during the placebo phase) (Table 2).
DISCUSSION
Data from previous studies indicate that 15 to 50% of patients with heart failure and a 
preserved ejection fraction are treated with nitrates.8–12 However, in our study, isosorbide 
mononitrate did not improve the daily activity level, sub-maximal exercise capacity (6-
minute walk distance), or perceptive exercise tolerance (post-walk dyspnea score), quality-
of-life scores, or NT-proBNP levels in such patients. Indeed, dose-dependent decreases in 
daily activity levels were seen among patients receiving isosorbide mono-nitrate.
Although the most effective entry criteria for clinical trials involving patients with heart 
failure with a preserved ejection fraction remain controversial,23 the entry criteria and 
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characteristics of the patients in our study were consistent with those in several recent 
studies (Tables S2, S3, and S4 in the Supplementary Appendix). The NT-proBNP levels 
were lower in our study than in trials requiring an elevated NT-proBNP level for 
enrollment,24,25 since we did not require elevated NT-proBNP levels at study entry if there 
was other objective evidence of heart failure. Because the primary outcome assessment was 
based on the activity levels of patients, we required that patients report heart-failure–related 
symptoms as the primary reason they were less active than they desired to be.
We speculated that measures of daily activity using accelerometer-derived data might be 
more sensitive to the overall effect of a therapy than intermittent repetition of coached 
exercise tests or memory-dependent quality-of-life questionnaires. Accelerometer data are 
high-density, quantitative, and collected continuously under conditions of daily living.18,19 
Furthermore, the ultimate goal of therapies that are prescribed to improve exercise tolerance 
is indeed to facilitate activity. Inactivity promotes further deconditioning and frailty among 
patients with heart failure3 and is independently associated with both the incidence and 
deleterious outcomes of heart failure.26–28
If behavioral or environmental factors prominently influence a patient’s willingness or 
ability to be active, improved exercise tolerance may not lead to increased activity. 
However, our patients indicated that their activity was primarily limited by their heart-
failure symptoms. Furthermore, we observed a decrease in activity levels with isosorbide 
mononitrate, rather than no change. The decrease in activity occurred in the absence of 
adverse effects on submaximal exercise capacity or perceptive exercise tolerance, as 
assessed on the 6-minute walk test and in association with directionally adverse, albeit not 
significant, effects on quality-of-life scores. These findings suggest that activity levels were 
sensitive to adverse effects of isosorbide mononitrate beyond the numerically higher rate of 
overt symptoms requiring study-drug discontinuation.
Absolute values for accelerometer units and the activity time per day that is based on such 
units are highly sensitive to the device design, body location, data-acquisition mode, 
analytics, activity threshold values, and patient population.18,19 Thus, a comparison with 
other studies is difficult. During the 120-mg phase, patients who received isosorbide 
mononitrate were active for 0.3 hours (18 minutes) less per day than were those who 
received placebo. Observational studies using uniaxial, chest-worn accelerometer data from 
implanted pacing or defibrillator devices in patients with heart failure and a reduced ejection 
have shown that even a 10-minute reduction in activity per day was associated with adverse 
outcomes.28 These data would suggest that the reductions in activity with isosorbide 
mononitrate that we observed were clinically relevant. Each accelerometer was calibrated 
during production, but there are no validation studies with this accelerometer in patients 
with heart failure. Similar accelerometers have been shown to capture low levels of daily 
physical activity with a high degree of sensitivity.29–32
The lack of improvement in exercise tolerance and the adverse effect on daily activity levels 
may relate to the pathophysiology of heart failure with a preserved ejection fraction. 
Increased ventricular systolic and vascular stiffness, autonomic dysfunction, chronotropic 
incompetence, and altered baroreflex sensitivity are common and may limit the 
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hemodynamic benefits of nitrates.14,15,33 Our post hoc analysis indicated decreases in blood 
pressure with isosorbide mono-nitrate. In addition, the potential for drug interactions and 
adverse drug reactions increases with an older age, obesity, coexisting illnesses, and 
polypharmacy, all of which are characteristic of our study population.16,17
One limitation of our trial is that we used a rapid dose escalation of the study drug. Isosor-
bide mononitrate or placebo was initiated at a dose of 30 mg daily for 1 week and 60 mg 
daily for 1 week before reaching the target dose of 120 mg daily. Given the sensitivity of 
patients with heart failure with a preserved ejection fraction to changes in hemodynamics, it 
is possible that a more gradual dose escalation might have yielded different results. We also 
speculate that inorganic nitrite or nitrate34–36 may enhance nitric oxide bioavailability 
preferentially during exercise and be more effective and have fewer side effects than do 
organic nitrates.
In conclusion, in patients with heart failure with a preserved ejection fraction, the receipt of 
isosorbide mononitrate, as compared with placebo, decreased daily activity levels. In 
addition, receipt of isosorbide mononitrate did not improve submaximal exercise capacity, 
quality-of-life scores, or NT-proBNP levels in these patients.
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Figure 1. Primary and Secondary End Points for Activity Levels
Shown are the absolute values and differences between the two treatments (isosorbide 
mononitrate minus placebo) for the average daily arbitrary accelerometer units (Panel A) 
and hours of activity per day (Panel B) during the 120-mg phase and for daily arbitrary 
accelerometer units for all three doses (30 mg, 60 mg, and 120 mg) combined (Panel C). The 
arbitrary accelerometer units were stored as 15-minute cumulative accelerometer units (96 
data points per day) and were totaled over a 24-hour period to provide daily accelerometer 
units. The I bars indicate 95% confidence intervals.
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Figure 2. Change in Activity Levels with Increasing Doses of Isosorbide Mononitrate or Placebo
Shown are the changes from baseline in the average daily arbitrary accelerometer units 
according to the dose of iso-sorbide mononitrate and placebo in the two study groups and 
the corresponding treatment differences (dose value minus baseline value). Among the 
patients who received placebo, 89 received the 30-mg dose, 91 received the 60-mg dose, and 
93 received the 120-mg dose. Among the patients who received isosorbide mononitrate, 85 
received the 30-mg dose, 87 received the 60-mg dose, and 89 received the 120-mg dose. The 
I bars indicate 95% confidence intervals.
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Figure 3. Average Daily Arbitrary Accelerometer Units, According to Subgroup
Shown are the average daily arbitrary accelerometer units in each of the prespecified 
subgroups and the between-group treatment differences and 95% confidence intervals. The 
term “nitrate tolerance” refers to the decreasing effect of nitrates in patients after long-term 
exposure to this drug class. Inhibitors of nitrate tolerance include renin–angiotensin–
aldosterone antagonists, carvedilol, statins, and hydralazine. Since only four patients were 
treated with hydralazine, the subgroup analysis for this variable alone is not shown. ACE 
denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, ECG 
electrocardiography, and NT-proBNP N-terminal pro–brain natriuretic peptide.
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Table 1
Characteristics of the Patients at Baseline.*
Characteristic Placebo First (N = 59)
Isosorbide Mononitrate First 
(N = 51)
Age — yr 69±10 69±9
Female sex — no. (%) 38 (64) 25 (49)
White race — no. (%)† 54 (92) 44 (86)
Body-mass index‡ 35.1±8.7 36.2±8.0
Functional measures
 New York Heart Association classification — no. (%)§
  II 33 (56) 25 (49)
  III 24 (41) 26 (51)
 Overall score on Kansas City Cardiomyopathy Questionnaire¶ 58.0±24.6 53.6±23.8
 Total score on Minnesota Living with Heart Failure Questionnaire|| 43.3±22.0 46.0±25.6
 Six-minute walk distance — m 321±112 300±127
 Daily no. of arbitrary accelerometer units** 9607±5439 9889±4730
 No. of hours of activity per day** 9.2±2.3 9.6±2.1
Physical examination
 Systolic blood pressure — mm Hg 132±18 129±14
 Heart rate — beats/min 70±12 73±13
 Elevated jugular venous pressure — no./total no. (%) 17/59 (29) 20/50 (40)
 Edema — no./total no. (%) 34/58 (59) 32/51 (63)
Medical history — no./total no. (%)
 Hospitalization for heart failure 16/59 (27) 12/51 (24)
 Hypertension 54/59 (92) 45/51 (88)
 Ischemic heart disease 36/59 (61) 32/51 (63)
 History of atrial fibrillation 20/59 (34) 19/51 (37)
 Diabetes mellitus 21/59 (36) 22/51 (43)
 Chronic obstructive pulmonary disease 10/59 (17) 6/51 (12)
 Sleep apnea 28/56 (50) 29/51 (57)
 Anemia†† 18/59 (31) 18/50 (36)
 Chronic kidney disease, stage ≥3‡‡ 32/59 (54) 21/50 (42)
 Depression treated with prescription drug 22/59 (37) 14/51 (27)
Cardiovascular medication at enrollment — no. (%)
 Loop diuretic 36 (61) 36 (71)
 Hydrochlorothiazide 6 (10) 6 (12)
 ACE inhibitor or ARB 36 (61) 34 (67)
 Beta-blocker 41 (69) 36 (71)
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Characteristic Placebo First (N = 59)
Isosorbide Mononitrate First 
(N = 51)
 Aldosterone antagonist 13 (22) 14 (27)
 Calcium-channel blocker 24 (41) 10 (20)
 Lipid-lowering agent 42 (71) 32 (63)
 Antiplatelet or anticoagulant agent 47 (80) 43 (84)
Laboratory or echocardiographic measure
 Local laboratory creatinine — mg/dl 1.2±0.4 1.2±0.4
 Median core laboratory NT-proBNP (IQR) — pg/ml 248 (120–644) 210 (102–511)
 Ejection fraction — % 65±9 62±8
 Relative wall thickness >0.41 — no./total no. (%) 26/58 (45) 24/48 (50)
 Ratio of early mitral inflow velocity to early diastolic medial mitral annular 
velocity
15±7 15±10
 Left atrial volume — ml/m2 of body-surface area 38.9±11.6 41.2±19.1
*
Plus–minus values are means ±SD. In this crossover study, patients were assigned to 6 weeks of placebo first with crossover to 6 weeks of 
isosorbide mononitrate or to 6 weeks of isosorbide mononitrate first with crossover to 6 weeks of placebo. The same patients were compared 
during the two treatment periods. There were no significant differences between the two groups except for the use of a calcium-channel blocker (P 
= 0.02) and the ejection fraction (P = 0.03). ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, and NT-proBNP N-
terminal pro–brain natriuretic peptide. To convert the values for creatinine to micromoles per liter, multiply by 88.4.
†
Race was self-reported.
‡
The body-mass index is the weight in kilograms divided by the square of the height in meters.
§
In the placebo-first group, one patient was classified as having class I symptoms and another as having class IV symptoms.
¶Overall scores on the Kansas City Cardiomyopathy Questionnaire range from 1 to 100, with higher scores indicating better function.
||
Total scores on the Minnesota Living with Heart Failure Questionnaire range from 0 to 105, with higher scores indicating worse function.
**
This category was assessed during the baseline phase of period 1 before the initiation of isosorbide mononitrate or placebo.
††Anemia was defined as a hemoglobin level of less than 13 g per deciliter for men and less than 12 g per deciliter for women.
‡‡Chronic kidney disease of stage 3 or greater was defined as a glomerular filtration rate of 60 ml per minute per 1.73 m2 of body-surface area or 
less, as calculated by the Modification of Diet in Renal Disease equation.
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Table 2
Efficacy and Safety End Points.
End Point Placebo (N = 110)
Isosorbide Mononitrate (N 
= 110) Treatment Difference* P Value
mean (95% CI)
Efficacy
Activity as assessed on accelerometry
 Daily arbitrary accelerometer units during 120-
mg phase: primary end point
9303 (8884–9723) 8922 (8500–9345) −381 (−780 to 17) 0.06
 No. of hours of activity per day 9.31 (9.05–9.56) 9.01 (8.75–9.27) −0.30 (−0.55 to −0.05) 0.02
 Daily arbitrary accelerometer units for all 
treatment doses
9623 (9271–9976) 9185 (8822–9547) −439 (−792 to −86) 0.02
Six-minute walk test
 Distance — m 321 (307–336) 322 (307–336) 0.57 (−9.63 to 10.78) 0.91
 Borg dyspnea score† 3.97 (3.59–4.34) 3.89 (3.52–4.26) −0.07 (−0.50 to 0.36) 0.74
Quality of life
 Overall score on Kansas City Cardiomyopathy 
Questionnaire
61.6 (58.9– 64.4) 59.7 (57.0–62.5) −1.91 (−4.55 to 0.74) 0.16
 Total score on Minnesota Living with Heart 
Failure Questionnaire
35.4 (31.6– 39.2) 37.0 (33.3–40.6) 1.62 (−1.98 to 5.23) 0.37
NT-proBNP — pg/ml 497 (422– 572) 550 (475–625) 53 (−33 to 138) 0.22
Blood pressure — mm Hg
 Systolic 129 (125–132) 125 (122–128) −3.7 (−7.2 to −0.3) 0.04
 Diastolic 70 (69–72) 69 (67–71) −1.6 (−3.5 to 0.3) 0.10
Mean arterial blood pressure — mm Hg 90 (88–92) 88 (86–90) −2.3 (−4.4 to −0.2) 0.03
Safety
no. of patients with event
Any event of interest 6 14
 Arrhythmia 2 2
 Worsening heart failure 1 5
 Stroke or transient ischemic attack 0 1
 Presyncope or syncope 3 6
 Worsening renal function 0 0
Serious adverse event
 Death 0 0
 Other serious adverse event‡ 1 2
*
The treatment difference is the value in the isosorbide mononitrate group minus the value in the placebo group.
†
The Borg dyspnea score ranges from 1 to 10, with higher scores indicating greater severity.
‡One patient had fecaloma and urinary retention during the baseline period before starting any study drug and cellulitis while taking isosor-bide 
mononitrate, one patient had herpes zoster while taking isosorbide mononitrate, and one patient had an exacerbation of chronic obstructive 
pulmonary disease while taking placebo.
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